Multidisciplinary Approach To Neoadjuvant Endocrine Therapy In Breast Cancer: A Comprehensive Review

Abordagem Multidisciplinar Em Hormonioterapia Neoadjuvante No Câncer De Mama: Uma Revisão

dc.creatorReinert
dc.creatorTomás; Ramalho
dc.creatorSusana; Gonçalves
dc.creatorRodrigo; Barrios
dc.creatorCarlos Henrique; Graudenz
dc.creatorMarcia Silveira; Bines
dc.creatorJosé
dc.date2016
dc.date2017-08-30T17:37:59Z
dc.date2017-08-30T17:37:59Z
dc.date.accessioned2018-03-29T05:30:58Z
dc.date.available2018-03-29T05:30:58Z
dc.identifierRevista Brasileira De Ginecologia E Obstetrícia. Federação Brasileira Das Sociedades De Ginecologia E Obstetrícia, v. 38, n. 2, p. 615 - 622
dc.identifier0100-7203
dc.identifierS0100-72032016001200615
dc.identifierhttp://www.scielo.br/scielo.php?pid=S0100-72032016001200615&script=sci_abstract&tlng=pt
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/324954
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1359172
dc.descriptionBreast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HRþ) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemo-therapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2þ) tumors. Neoadjuvant endocrine therapy (NET) is an option for selected patients with HRþ locally advanced breast cancer. Neoadjuvant endocrine therapy has a favorable toxicity profile, and is associated with benefits such as having low cost and being more easily available even for cancer care professionals outside major urban areas or tertiary centers. These factors are particularly relevant, as 70% of breast cancer deaths occur in women from low-income and middle-income countries. Additionally, NET is being increasingly explored, not simply to allow for less extensive surgery, but also as a scientific tool, with the use of biomarkers to predict outcomes in adjuvant trials and for the individual patient. This review details the current and most relevant evidence about NET for breast cancer as well as the future directions of this field.
dc.description38
dc.description2
dc.description615
dc.description622
dc.languageIngles
dc.publisherFederação Brasileira das Sociedades de Ginecologia e Obstetrícia
dc.relationRevista Brasileira de Ginecologia e Obstetrícia
dc.rightsaberto
dc.sourceScielo
dc.subjectBreast Neoplasm
dc.subjectDrug Therapy
dc.subjectTamoxifen
dc.subjectAromatase Inhibitors
dc.subjectNeoplasias Da Mama
dc.subjectFarmacoterapia
dc.subjectTamoxifeno
dc.subjectInibidores Da Aromatase
dc.titleMultidisciplinary Approach To Neoadjuvant Endocrine Therapy In Breast Cancer: A Comprehensive Review
dc.titleAbordagem Multidisciplinar Em Hormonioterapia Neoadjuvante No Câncer De Mama: Uma Revisão
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución